A scalable aptamer-based electrochemical biosensor for rapid detection of sars-COV-2 from saliva
Ended Project Grant Awarded Last action
- Award ID
- R44DE030842
- Recipient
-
Mpod Inc. UEI JELTXBVC4DZ1
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,977,827
Award facts
- Assistance listing
- 93.360 Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development
- Completion date
- Originally
- Funding
-
- $2,475,579.00 Federal
- $502,248.00 Non-federal
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- New York, NY 10013, USA
Award details come from USAspending.gov.
Description
- Abstract
- The covid-19 pandemic is a critical global public health emergency and many countries are failing to contain the virus's spread due to slow and insufficient testing. While several diagnostic methods are now available, most tests are either reagent-intensive and must be done in clia-approved labs, making them expensive and slow to report results, or rapid and inexpensive, but potentially lacking in sensitivity. In the U.S., seriously ILL and high- risk patients have been prioritized for testing, causing states to miss mild and asymptomatic cases, some of which are the most effective spreaders of the virus. However, expanding testing has been a challenge due to shortages of sampling swabs and key reagents for nucleic acid amplification-based tests, which are the most popular option. Testing capabilities must be expanded exponentially to enable mass population-level testing of all patients, healthcare workers and their families, other critical key workers, and the wider community in order to bring the pandemic under control. Mpod proposes to expand testing capabilities through a novel biosensor that will use oligonucleotide molecules called aptamers to bind to unique sites on the sars-COV-2 virus. Aptamers have similar binding affinities to antibodies, but due to their smaller size, they are more agile, making them particularly suited for high-specificity binding. To complete the test, a saliva sample will be loaded onto a test strip containing aptamers immobilized onto gold electrodes. The gold-electrode test strip will be inserted into the mpod dtct, a proprietary electrochemical test platform where virus-bound aptamers will be detected via cyclic voltammetry, triggering a positive result. The result is sent wirelessly via a mobile APP, which sends encrypted data on to the cloud for storage and to public health agencies for enhanced data collection, tracking, and tracing of covid-19. The APP will also include a backend database to help businesses, manufacturers, schools, and large institutions track tested individuals' results and tailor specific public health responses. In order to further develop this technology and enable rapid deployment for timely covid-19 intervention, mpod plans to 1) select sars-COV-2-specific aptamers for use in electrode test strips with an optimized signal-to-noise ratio performance, 2) demonstrate sensitivity and specificity of a low-cost, miniaturized potentiostat test strip for use as a covid-19 POC or OTC diagnostic, 3) complete and test a fully-fledged digital infrastructure for data collection, tracking, and tracing of covid-19 test results via the mpod mobile APP. This non-traditional approach will provide new testing capabilities with the potential to report results faster than standard RT-PCR tests and with greater accuracy and sensitivity compared to existing antigen-based diagnostics. Furthermore, once the system is developed, test strips with customized aptamers can be developed for rapid diagnosis of other pathogens, including future emerging pandemics, via routine POC and OTC testing.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $490,361 | $0 | |
| Amendment | $490,361 | $0 | |
| Amendment | $490,361 | $0 | |
| Amendment | $502,248 | $0 | |
| Original award | $502,248 | $502,248 |
Show all 13
Quick answers
Who received award R44DE030842?
R44DE030842 was awarded to Mpod Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on December 21, 2020.
How much is award R44DE030842 worth?
$2,977,827 has been obligated on R44DE030842: $2,475,579 in federal funding and $502,248 in non-federal funding.
Which agency awarded R44DE030842?
National Institute of Dental and Craniofacial Research (National Institutes of Health) awarded R44DE030842, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award